Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City
Abdullah, K., Namik, M., Khaleel, I. (2023). Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City. EKB Journal Management System, 90(1), 1053-1056. doi: 10.21608/ejhm.2023.280209
Khalilda Khaleel Abdullah; Muzayyan Fadhly Namik; Iman Ismael Khaleel. "Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City". EKB Journal Management System, 90, 1, 2023, 1053-1056. doi: 10.21608/ejhm.2023.280209
Abdullah, K., Namik, M., Khaleel, I. (2023). 'Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City', EKB Journal Management System, 90(1), pp. 1053-1056. doi: 10.21608/ejhm.2023.280209
Abdullah, K., Namik, M., Khaleel, I. Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City. EKB Journal Management System, 2023; 90(1): 1053-1056. doi: 10.21608/ejhm.2023.280209

Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City

The Egyptian Journal of Hospital Medicine
Article 156, Volume 90, Issue 1, January 2023, Page 1053-1056  XML PDF (422.79 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2023.280209
View on SCiNiTO View on SCiNiTO
Authors
Khalilda Khaleel Abdullah email ; Muzayyan Fadhly Namik; Iman Ismael Khaleel
Abstract
Background: Metformin, an anti-hyperglycemic drug, treats type 2 diabetes with diet. It increases muscle glucose consumption, maintains blood levels, and does not cause severe hypoglycemia.
Aim: To evaluate the effect of metformin on some plasminogen and cortisol variables and some hematological variables represented in the percentage of compact red blood cells, hemoglobin concentration, total number of red blood cells, and white blood cells in patients with type 2 diabetes.
Subjects and Method: 90 patients with type 2 diabetes and patients who used metformin treatment twice a day continued for three months, six months, and one year were included, according to a questionnaire. After confirming the status of type 2 diabetes through laboratory tests, samples were taken. They were divided into four groups according to the period used in the treatment.
Results: The results indicated that treatment with metformin led to a significant decrease in the level of Plasminogen Activator-1 (PAI-1) and cortisol hormones, in addition, to the decline in hematological indices, packed cell volume (PCV), hemoglobin (Hb), red blood cells (RBCs) and white blood cells (WBCs) within works 2, 3 and 4 compared to the control group.
Conclusion: Metformin may improve the risk of atherosclerotic disease that may occur due to diabetes by lowering blood glucose, such as improving endothelial function, decreasing inflammatory activity, and decreasing blood parameters during treatment, which may be related to anemia.
 
Keywords
Diabetes; Metformin; Plasminogen; PCV; Hb; WBC; RBC
Statistics
Article View: 164
PDF Download: 219